[1]李 丹,赵 飞,王树庚.疏肝健脾散结汤联合肝动脉插管化疗栓塞术治疗原发性肝癌疗效研究[J].陕西中医,2021,(6):728-731.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.012]
　LI Dan,ZHAO Fei,WANG Shugeng.Effect of Shugan Jianpi Sanjie decoction combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer[J].,2021,(6):728-731.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.012]
点击复制

疏肝健脾散结汤联合肝动脉插管化疗栓塞术治疗原发性肝癌疗效研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2021年6期
页码:
728-731
栏目:
临床研究
出版日期:
2021-06-05

文章信息/Info

Title:
Effect of Shugan Jianpi Sanjie decoction combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer
作者:
李 丹; 赵 飞; 王树庚
(秦皇岛市第二医院,河北 秦皇岛 066000)
Author(s):
LI Dan; ZHAO Fei; WANG Shugeng
(Qinhuangdao Second Hospital,Qinhuangdao 066000,China)
关键词:
原发性肝癌;  疏肝健脾散结汤;  肝动脉插管化疗栓塞术;  中医证候积分;  肝功能;  免疫功能
Keywords:
Primary liver cancer;  Shugan Jianpi Sanjie decoction;  Transcatheter arterial chemoembolizatio;  TCM syndrome score;  Liver function;  Immune function
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7369.2020.06.012
文献标志码:
A
摘要:
目的:探讨疏肝健脾散结汤联合肝动脉插管化疗栓塞术对原发性肝癌的治疗效果。方法:选取原发性肝癌患者80例,按照随机数字表法分为对照组、观察组,各40例。对照组在肝动脉插管化疗栓塞术后行常规西医疗法,观察组在对照组基础上应用疏肝健脾散结汤。比较两组患者总缓解率、中医证候积分、肝功能和免疫功能。结果:观察组总缓解率为55.00%,高于对照组的32.50%; 观察组中医证候总积分为(8.10±1.42)分,低于对照组的(12.92±2.16)分,组间差异有统计学意义(P<0.05)。两组治疗前肝功能和免疫功能比较,差异无统计学意义(均P>0.05)。观察组治疗后天门冬氨酸氨基转移酶、丙氨酸氨基转移酶、甲胎蛋白、免疫球蛋白A和免疫球蛋白G水平低于对照组,自然杀伤细胞和CD4+水平则高于对照组,组间差异有统计学意义(均P<0.05)。结论:原发性肝癌患者给予肝动脉插管化疗栓塞术联合疏肝健脾散结汤治疗,临床疗效较好,可缓解患者临床症状,对患者肝功能、免疫功能改善作用也较好。
Abstract:
Objective:To investigate effect of Shugan Jianpi Sanjie decoction combined with transcatheter arterial chemoembolization(TACE)for primary liver cancer.Methods:80 patients with primary liver cancer were selected and divided into control group and observation group,40 cases in each group,according to random number table method.The control group received conventional western medicine treatment after TACE,and the observation group received Shugan Jianpi Sanjie decoction on the basis of the control group.The total remission rate,TCM syndrome score,liver function and immune function were compared between the two groups.Results:The total remission rate of observation group was 55.00% higher than 32.50% of the control group.The TCM syndrome score of the observation group was(8.10±1.42)points lower than that of the control group(12.92±2.16)points,difference statistically significant(P<0.05).Before treatment,there was no significant difference in liver function and immune function between the two groups(all P>0.05).After treatment,the levels of aspartic aminotransferase,alanine aminotransferase,alpha-foetal protein,immunoglobulin A and immunoglobulin G in the observation group were lower than those in the control group,while the levels of natural killer cells and CD4+ were higher than those in the control group,with statistical significance(all P<0.05).Conclusion:Patients with primary liver cancer received transcatheter arterial chemoembolization combined with Shugan Jianpi Sanjie decoction,clinical effect is better,and can relieve the clinical symptoms of patients,the improvement of liver function and immune function is also better.

参考文献/References:

[1] 尹树君,金琦智,马玉靖,等.原发性肝癌血清蛋白质标志物研究进展[J].实用医院临床杂志,2019,16(2):261-264.
[2] 郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析[J].陕西医学杂志,2019,48(7):850-852.
[3] 李 珣,张祥林.肝动脉化疗栓塞联合恩替卡韦对原发性肝癌治疗效果及对患者血清中恶性肿瘤特异性生长因子的影响[J].陕西医学杂志,2019,48(7):873-875.
[4] 滕伟峰,毛琦琪,俞丹松,等.消癥益肝片联合mFOLFOX6方案治疗晚期原发性肝癌临床研究[J].中华中医药学刊,2020,38(4):212-216.
[5] 李国炜,温小凤,解发良,等.祛痰化瘀解毒散结法联合疏肝健脾汤治疗肝脾失调,痰瘀互结证甲亢突眼症临床研究[J].陕西中医,2020,41(6):758-761.
[6] 陈 悦,龚作炯,王鲁文.肝脏疾病诊疗进展[M].武汉:湖北科学技术出版社,2008:11-13.
[7] 国家中医药管理局中医肝病重点专科写作组.中医肝病诊疗常规[M].上海:上海科技教育出版社,2005:14-15.
[8] 王吉耀.现代肝病诊断与治疗[M].上海:复旦大学出版社,2007:20-22.
[9] 国家中医药管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:44-47.
[10] 袁响林.中晚期原发性肝癌的降期转化治疗[J].临床肝胆病杂志,2020,36(2):29-33.
[11] 孙玉莉,王伟芹,孙建光,等.尹常健教授治疗原发性肝癌临证用药特点[J].中西医结合肝病杂志,2020,30(5):70-71.
[12] 蒋锐沅,荣 震,满婷婷,等.基于“阳化气,阴成形”理论探讨原发性肝癌的病因与治法[J].四川中医,2020,38(4):37-40.
[13] 顾 冲,吴春城,唐金模.疏肝健脾汤治疗肝硬化患者应用及对炎性因子的影响[J].中医临床研究,2019,11(22):10-13.
[14] 朱亚玲,易峰涛.复方丹参注射液联合伽马刀治疗对原发性肝癌患者免疫功能的影响[J].中西医结合肝病杂志,2020,30(2):21-23.
[15] 翁佳雷,尹毅锐,周晨浩,等.乙肝免疫球蛋白预防乙肝相关肝癌患者术后病毒再激活的效果研究[J].肝胆胰外科杂志,2020,32(4):205-210.
[16] 程 熠,吴莹莹,刘东伯,等.肝癌免疫细胞浸润模式及与预后的相关性分析[J].华中科技大学学报:医学版,2019,48(3):276-280.
[17] 王姜琳,杨慧健,于修文,等.原发性肝癌患者免疫细胞变化及其与HBV-DNA、HBeAg和肿瘤大小的关系[J].检验医学与临床,2019,16(12):1659-1661.
[18] 张玉萍,李婵桂,邹 莹.黄芪四君子汤联合成分输血对肝癌介入术后免疫功能影响的研究[J].新中医,2020,52(9):46-48.
[19] 臧文华,胡久略,唐德才,等.黄芪,莪术联合顺铂对人肝癌裸鼠TF,HGF,FVⅡ表达的影响[J].中华中医药学刊,2020,38(3):108-111.
[20] 李明襄,王海晓,叶舒婷,等.四君子汤活性成分抗肝癌研究现状[J].内蒙古中医药,2019,38(12):141-143.

相似文献/References:

[1]乔喜婷,王 昊△,杨 林,等.复元活血汤合化积丸联合肝动脉栓塞化疗术治疗原发性肝癌临床研究*[J].陕西中医,2019,(8):998.
　QIAO Xiting,WANG Hao,YANG Lin,et al.Fuyuan Huoxue decoction plus Huaji pills and hepatic artery embolization in the treatment of primary liver cancer[J].,2019,(6):998.
[2]赵培西,许建秦,袁 彬,等.扶正抗癌方治疗肝癌肝郁脾虚瘀毒证临床研究[J].陕西中医,2022,(12):1746.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.022]
[3]周 林,肖 康,夏建辉.八珍汤加减辅助治疗原发性肝癌疗效及对患者外周血Th17/Treg平衡和不良反应的影响[J].陕西中医,2023,(9):1216.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.013]
　ZHOU Lin,XIAO Kang,XIA Jianhui.Effect of modified Bazhen decoction adjuvant therapy on peripheral blood Th17/Treg balance and adverse reactions in patients with primary liver cancer[J].,2023,(6):1216.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.013]
[4]徐巧笑,胡振斌,莫莎莎,等.从“虚、毒、瘀”浅谈原发性肝癌病机和治疗[J].陕西中医,2023,(10):1431.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.022]
　XU Qiaoxiao,HU Zhenbin,MO Shasha,et al.Discussion on pathogenesis and treatment of primary liver cancer from the perspective of “deficiency,poison,and blood stasis”[J].,2023,(6):1431.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.022]
[5]吉 银,戴 铭,王振常,等.逍遥散合大黄虫丸治疗原发性肝癌经肝动脉化疗栓塞术后气滞血瘀型疗效研究[J].陕西中医,2024,(2):187.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.008]
　JI Yin,DAI Ming,WANG Zhenchang,et al.Treatment of primary hepatocellular carcinoma qi stagnation and blood stasis type patients after TACE with Xiaoyao San combined with Dahuang Zhechong pill[J].,2024,(6):187.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.008]
[6]李俊漪,徐 剑.龙胆泻肝汤对原发性肝癌肝动脉栓塞化疗术后患者肝功能及肿瘤标志物的影响研究[J].陕西中医,2024,(10):1353.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.012]
　LI Junyi,XU Jian.Longdan Xiegan decoction on liver function and tumor markers in patients with PHC after TACE[J].,2024,(6):1353.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.012]
[7]曹虹丽,彭廷云,陈青山,等.柴芍六君子汤对原发性肝癌患者化疗期间疗效及免疫功能的影响[J].陕西中医,2024,(11):1495.[doi:DOI:10.3969/j.issn.1000-7369.2024.11.011]
　CAO Hongli,PENG Yanyun,CHEN Qingshan,et al.Effect of Chaishao Liujunzi decoction on therapeutic effect and immune function of primary liver cancer during chemotherapy[J].,2024,(6):1495.[doi:DOI:10.3969/j.issn.1000-7369.2024.11.011]

备注/Memo

备注/Memo:
基金项目:河北省医学科学研究计划项目(20191368)
更新日期/Last Update: 2021-06-09